Search Results - "Simko, Robert J"

The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus by Toth, Peter P, Simko, Robert J, Palli, Swetha Rao, Koselleck, Dawn, Quimbo, Ralph A, Cziraky, Mark J

“…Few large-scale, real-world studies have assessed the relative associations of lipid fractions with diabetic microvascular events. The main objective of this…”
Get full text

Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence by Balu, Sanjeev, Simko, Robert J., Quimbo, Ralph M., Cziraky, Mark J.

“…Abstract Objective: To compare medication adherence between patients initiating fixed-dose combination versus multi-pill combination dyslipidemia therapies and…”
Get full text

Relative Effect of Fenofibrate and Equivalent Statin Therapies on the Attributable Costs of Macrovascular Complications Following Type II Diabetes by Simko, Robert J., PharmD, Toth, Peter P., MD, PhD, Palli, S.R, Quimbo, R.A

Get full text

Relative Impact of Fenofibrate and Equivalent Statin Therapies on the Risk of Macrovascular Complications Following Type II Diabetes by Simko, Robert J., PharmD, Toth, Peter P., MD, PhD, Palli, S.R, Quimbo, R.A

Get full text

Development of an Interactive Model of the Burden of Future Coronary Heart Disease From an Employer Perspective by Lang, Kathleen, Korn, Jonathan R., Simko, Robert J., Zachry, Woodie M., Patel, Nikil V., Nair, Radhika, Menzin, Joseph

“…Objective: To create a computer-based model for employers to better understand the burden of coronary heart disease (CHD) to their organizations. Methods: A…”
Get full text

Attainment of combined optimal lipid values and the impact of lipid medication on cardiovascular outcomes and costs in a commercially insured population in the US by Quimbo, Ralph A, Simko, Robert J, Cziraky, Mark J, Burge, Russel T

“…To determine factors associated with the achievement of optimal lipid values (OLVs) and subsequent impact on clinical and economic outcomes. An observational…”
Get more information

Patient preferences for thrombolytic therapy in acute myocardial infarction by Stanek, E J, Cheng, J W, Peeples, P J, Simko, R J, Spinler, S A

“…Despite extensive professional debate regarding the optimal thrombolytic therapy strategy in acute myocardial infarction (AMI), patient preferences have not…”
Get more information

Treatment patterns for heart failure in a primary care environment by Simko, R J, Stanek, E J

“…Little published information regarding current pharmacotherapeutic treatment patterns for congestive heart failure (CHF) in nonacademic, ambulatory care…”
Get full text

Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin by Simko, R J, Tsung, F F, Stanek, E J

“…To compare and contrast the activated partial thromboplastin time (aPTT) and the activated clotting time (ACT) for the therapeutic monitoring of heparin…”
Get more information

Prolonged Quinidine Half‐life with Associated Toxicity in a Patient with Hepatic Failure by Stanek, Eric J., Simko, Robert J., DeNofrio, David, Pavri, Behzad B.

“…A markedly prolonged quinidine elimination half‐life due to hepatic failure and resultant quinidine toxicity occurred in a 57‐year‐old man with a history of…”
Get full text

Prolonged Quinidine Half-life with Associated Toxicity in a Patient with Hepatic Failure by Stanek, Eric J., Simko, Robert J., DeNofrio, David, Pavri, Behzad B.

Get full text

Effects of naltrexone pellet implantation on morphine tolerance and physical dependence in the rat by Bhargava, H N, Matwyshyn, G A, Gerk, P M, Bozek, P S, Bailey, M D, Ko, K H, Simko, R J, Thorat, S N

“…1. The effect of naltrexone pellets containing either 10 or 30 mg of naltrexone base on the development of tolerance and physical dependence on morphine was…”
Get more information